Sector News

Haseeb Ahmad named new ABPI president

May 6, 2019
Life sciences

Novartis’ Haseeb Ahmad is set to become president of the The Association of the British Pharmaceutical Industry (ABPI), where he will take over the role vacated by Erik Nordkamp and lead on overseeing both the ABPI, the ABPI Board and the ABPI’s Code of Practice.

In his new role he will take advantage of the opportunities presented by science, technology and data to help get new medicines to patients faster, whilst promoting innovation and collaboration with the NHS and government, which will not only improve outcomes for patients but also boost the UK economy.

Haseeb said of his appointment: “We are in a golden era of medicines discovery, where innovative science is converging with a data and digital revolution. These forces are coming together to treat and potentially cure diseases on a scale the likes of which we’ve not seen before.”

Haseeb is Novartis UK country president and managing director UK & Ireland of Novartis, and has held senior in-country appointments, including managing director for MSD in Greece during the economic crisis, and above-country roles in Strategy, Operations, Sales and Marketing.

He continued, “The pharmaceutical industry, Government and the NHS must work together to ensure that patients can access innovative therapies and that we deliver the kind of healthcare that all of us in the UK deserve.”

Haseeb has previously led the American Chamber of Commerce Pharma Group, is a member of the ABPI board and Novartis European Executive Committee. He is recognised as a leader who enables winning performance by working collaboratively with customers and has a passion for innovation in healthcare delivery.

By Anna Smith

Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”